Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy

AIDS

Volumn 20, Issue 9, 2006, Pages 1253-1260

  Filippini, Pietro ^a   Coppola, Nicola ^a   Pisapia, Raffaella ^a   Scolastico, Carlo ^a   Marrocco, Cecilia ^a   Zaccariello, Antonella ^a   Nacca, Cesare ^b   Sagnelli, Caterina ^a   De Stefano, Giulio ^c   Ferraro, Teresa ^d   De Stefano, Carlo ^e   Sagnelli, Evangelista ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Azienda Ospedaliera San Sebastiano   (Italy)

^c Azienda Ospedaliera Matera   (Italy)

^d Azienda Ospedaliera di Catanzaro   (Italy)

^e Division of Infectious Diseases   (Italy)

Author keywords

HAART; Hepatic flare in HIV infection; HIV infection; Lamivudine treatment; Occult hepatitis B virus infection

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA DETERMINATION; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS CORE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL;

EID: 33745838654     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000232232.41877.2a     Document Type: Article

References (35)

1. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22-26.
2. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, Piccinino F. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32:1106-1110.
3. Koike K, Koboyashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998; 54:249-255.
4. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2:479-486.
5. Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, et al. Occult hepatitis B virus infection. Digest Liver Dis 2000; 32:822-826.
6. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely occult? Hepatology 2001; 34:194-203.
7. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27:1736-1742.
8. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and silent HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64:350-355.
9. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Stanzione M, Filippini P, et al. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. J Med Virol 2001; 65:681-687.
10. Zignego AL, Fontana R, Puliti S, Barbagli S, Monti M, Careccia G, et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997; 51:313-318.
11. Urashima T, Saigo K, Kobayashi S, Imaseki H, Matsubara H, Koide Y, et al. Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues. J Hepatol 1997; 26:771-778.
12. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxì A, et al. Hepatitis B virus mantains its prooncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126:102-110.
13. Nunez M, Rios P, Perez Olmeda M, Soriano V. Lack of occult hepatitis B virus infection in HIV-infected patients. AIDS 2002; 16:2099-2101.
14. Hofer M, Joller Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17:6-13.
15. Lok A, Liang R, Chiu E, Wong K, Chan T, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100:182-188.
16. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26:517-526.
17. Carpenter PA, Huang ML, Mc Donald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. Blood 2002; 99:4245-4246.
18. Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, Gunther S. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32:144-148.
19. Altfeld M, Rockstroh JK, Addo M, Kupfer B, Pult I, Will H. Reactivation of hepatitis B in a long term anti-HBs positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29:306-309.
20. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998; 12:1256.
21. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
22. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:426-431.
23. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81:213-227.
24. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, Clinton White A Jr, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
25. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. JAMA 2000; 28:381-390.
26. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002; 228:222-235.
27. Centers for Disease Control. Revised HIV classification system, AIDS definition. WV Med J 1993; 89:74.
28. Stuyver L, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF, and the HEP DART International Committee. Nomenclature of antiviral-resistance human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-757.
29. Neau D, Winnock M, Jouvencel AC, Faure M, Castera L, Legrand E, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005; 40:750-753.
30. Shire NJ, Rouster S, Rajicic N, Sherman KE. Occult hepatitis B in HIV infected patients. J Acquir Immune Defic Syndr 2004; 36:869-875.
31. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
32. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shismotohno K, Chiba T. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31:488-495.
33. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32:635-639.
34. Barlow GD, France AJ. Exacerbation of hepatitis B infection following cessation of lamivudine therapy. Int J STD AIDS 2000; 11:684.
35. Sellier P, Clevenbergh P, Mazeron MC, Cazals-Hatem D, Evans J, Cervoni J, et al. Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation of chronic hepatitis B virus infection. Scand J Infect Dis 2004; 36:533-535.